Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dara-VRdA followed by ASCT in newly diagnosed high-risk multiple myeloma
ChiCTR2300075660Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daratumumab, bortezomib, lenalidomide, dexamethasone and doxorubicin in multiple myeloma (MM), sponsored by Ruijin Hospital. Primary endpoint: MRD negative rate after completion of consolidation therapy. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
daratumumabbortezomiblenalidomidedexamethasonedoxorubicin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2300075660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075660.